PULMONARY FIBROSIS

This study is testing whether the drug sirolimus can prevent permanent lung scarring (fibrosis) in people hospitalized with severe COVID-19 pneumonia. Hospitalized patients will be randomly assigned to receive different doses of sirolimus or standard care alone. Researchers will …

This is a very early study to see if a protein extract made from donated human fat tissue is safe and helpful for people with pulmonary fibrosis, a serious lung scarring disease. Seven participants will inhale the extract as a mist seven times over several weeks. The main goal is…

This study aims to understand why and how the lungs scar in people with pulmonary fibrosis. Researchers will analyze leftover tissue from lung biopsies of 80 participants to look for unique genetic markers. The goal is to gather knowledge that could lead to new ways to diagnose a…

This study is observing patients in Spain who have pulmonary fibrosis and are taking the medication nintedanib. The goal is to see how satisfied they are with a special support program and to monitor their quality of life, symptoms, and medication use over one year. It is not tes…

This study aims to understand how often severe COVID-19 pneumonia leads to permanent lung scarring (pulmonary fibrosis). Researchers will review the medical records of 200 critically ill patients to identify who developed fibrosis, what factors increased the risk, and how it affe…

This study aims to understand the long-term health problems some people experience after having COVID-19, often called 'Long COVID.' Researchers will review the medical records of 500 adults who had COVID-19 and were treated at Vanderbilt clinics. The goal is to track recovery pa…

This study aims to understand what causes pulmonary fibrosis, a serious lung-scarring disease. Researchers will collect and analyze blood and tissue samples from about 315 people, including patients with fibrosis, their relatives, and healthy volunteers. The goal is to learn more…

This study aims to understand if having short telomeres (protective caps on chromosomes) is common in Israeli patients with fibrotic lung disease and if it predicts a worse outcome. Researchers will recruit 100 participants, including patients and healthy controls, to measure tel…